Laurus Labs shares are trading at RS. 579.50, reflecting a decline of 5.45 points (0.93%) from the previous close of RS. 584.95 on the BSE.

The stock opened at RS. 591.75, reaching an intraday high of RS. 592.00 and a low of RS. 577.00. A total of 14,922 shares have been traded so far.

This BSE Group 'A' stock, with a face value of RS. 2, hit its 52-week high of RS. 619.50 on 7 January 2025 and a 52-week low of RS. 358.70 on 25 January 2024. Over the past week, the stock's high and low were RS. 593.00 and RS. 554.65, respectively. The company's current market capitalization stands at RS. 31,225.42 crore.

In terms of shareholding, promoters hold 27.60%, while Institutions and Non-Institutions own 38.30% and 34.10%, respectively.

In regulatory developments, Laurus Labs' wholly-owned foreign subsidiary, Laurus Generics Inc. (LGI), underwent a Post-Marketing Adverse Drug Experience (PADE) inspection by the USFDA. The inspection, conducted between 13 January 2025 and 21 January 2025, assessed global practices for reporting adverse events related to Laurus Labs’ marketed products.

The inspection resulted in the issuance of a Form 483 with one observation, which the company has committed to addressing within the required timeframe.

Laurus Labs, a research-driven pharmaceutical company, is one of India’s top producers of Active Pharmaceutical Ingredients (APIs), especially for anti-retroviral (ARV) and Hepatitis C drugs. It also manufactures APIs for oncology and other therapeutic categories.